Premium
Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide
Author(s) -
Lagneux Caroline,
Lamontagne Daniel
Publication year - 2001
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0703902
Subject(s) - cardioprotection , pharmacology , lipopolysaccharide , synthetic cannabinoids , medicine , neuroscience , chemistry , cannabinoid , biology , ischemia , receptor
We have examined the involvement of the endocannabinoid system in the cardioprotection triggered by lipopolysaccharide (LPS). Rats were treated with saline or LPS (10 μg Kg −1 ). 24 h later, hearts were excised, retrogradely perfused, submitted to a low‐flow ischaemia (0.6 ml min −1 ) for 90 min and reperfused for 60 min. Some hearts were perfused with either SR 141716A (a cannabinoid CB 1 , receptor antagonist 1 μ M ), SR 144528 (a CB 2 receptor anagonist μ M ), NNLA (3 μ M ) or sodium nitroprusside (1 μ M ) 5 min before ischaemia and during the ischaemic period. The cardioprotective effects of LPS treatment, in terms of infarction and functional recovery, were not altered by the perfusion of SR 141716A but abolished by both SR 144528 and NNLA. Finally, SR 144528 abolished the beneficial effects of SNP perfusion. Our results suggest an involvement of endocannabinoids, acting through the CB 2 receptors, in the cardioprotection triggered by LPS against myocardial ischaemia. This could be attributed to a relationship between cannabinoids and NO. British Journal of Pharmacology (2001) 132 , 793–796; doi: 10.1038/sj.bjp.0703902